000280241 001__ 280241
000280241 005__ 20250831001816.0
000280241 0247_ $$2doi$$a10.1111/ene.70289
000280241 0247_ $$2pmid$$apmid:40729416
000280241 0247_ $$2pmc$$apmc:PMC12306683
000280241 0247_ $$2ISSN$$a1351-5101
000280241 0247_ $$2ISSN$$a1468-1331
000280241 0247_ $$2altmetric$$aaltmetric:179793230
000280241 037__ $$aDZNE-2025-00919
000280241 041__ $$aEnglish
000280241 082__ $$a610
000280241 1001_ $$0P:(DE-2719)9000336$$aWalter, Uwe$$b0$$eFirst author
000280241 245__ $$aSystematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications.
000280241 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000280241 3367_ $$2DRIVER$$aarticle
000280241 3367_ $$2DataCite$$aOutput Types/Journal article
000280241 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756201499_31524$$xReview Article
000280241 3367_ $$2BibTeX$$aARTICLE
000280241 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280241 3367_ $$00$$2EndNote$$aJournal Article
000280241 520__ $$aBotulinum neurotoxin A (BoNT-A) is recommended for the treatment of cervical dystonia (CD), spasticity, and blepharospasm. Some patients treated with BoNT-A have been reported to develop neutralizing antibodies (NAbs) against BoNT-A, which may result in reduced efficacy and, in some cases, secondary treatment failure (STF). Our aim was to investigate the incidence of STF and NAb positivity after treatment with one of three commercially-available BoNT-A formulations.A systematic review and meta-analysis of STF and/or NAb positivity after treatment with abobotulinumtoxinA, incobotulinumtoxinA, or onabotulinumtoxinA in patients with CD, spasticity, or blepharospasm was conducted using PubMed, Embase, and Google Scholar.Twenty-nine unique studies reported in 29 publications assessed NAb positivity and were included. The meta-analysis showed that the proportions of patients developing STF were significantly higher after treatment with abobotulinumtoxinA or onabotulinumtoxinA than with incobotulinumtoxinA for CD or spasticity. Depending on the antibody test used, the proportions of patients developing NAbs were also significantly higher after treatment with abobotulinumtoxinA or onabotulinumtoxinA than with incobotulinumtoxinA for CD or spasticity. When data for all indications were pooled, proportions of NAb-positive patients were numerically higher with increasing mean doses of abobotulinumtoxinA or onabotulinumtoxinA. No patients treated exclusively with incobotulinumtoxinA were found to have developed immunogenic STF or persistent NAbs.The risk of developing STF and NAbs appears to vary with indication and BoNT-A formulation. When the efficacy and safety of formulations are comparable, incobotulinumtoxinA may be recommended to avoid developing STF and immunogenicity, particularly for patients requiring higher doses and repeated treatments.
000280241 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280241 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280241 650_7 $$2Other$$ablepharospasm
000280241 650_7 $$2Other$$abotulinum toxin
000280241 650_7 $$2Other$$acervical dystonia
000280241 650_7 $$2Other$$aimmunogenicity
000280241 650_7 $$2Other$$aspasticity
000280241 650_7 $$0EC 3.4.24.69$$2NLM Chemicals$$aBotulinum Toxins, Type A
000280241 650_7 $$2NLM Chemicals$$aAntibodies, Neutralizing
000280241 650_7 $$2NLM Chemicals$$aNeuromuscular Agents
000280241 650_7 $$0EC 3.4.24.69$$2NLM Chemicals$$aabobotulinumtoxinA
000280241 650_7 $$0EC 3.4.24.69$$2NLM Chemicals$$aincobotulinumtoxinA
000280241 650_7 $$0EC 3.4.24.69$$2NLM Chemicals$$aonabotulinum toxin A
000280241 650_2 $$2MeSH$$aHumans
000280241 650_2 $$2MeSH$$aBotulinum Toxins, Type A: therapeutic use
000280241 650_2 $$2MeSH$$aBotulinum Toxins, Type A: immunology
000280241 650_2 $$2MeSH$$aBotulinum Toxins, Type A: adverse effects
000280241 650_2 $$2MeSH$$aMuscle Spasticity: drug therapy
000280241 650_2 $$2MeSH$$aMuscle Spasticity: immunology
000280241 650_2 $$2MeSH$$aTorticollis: drug therapy
000280241 650_2 $$2MeSH$$aTorticollis: immunology
000280241 650_2 $$2MeSH$$aTreatment Failure
000280241 650_2 $$2MeSH$$aAntibodies, Neutralizing: blood
000280241 650_2 $$2MeSH$$aAntibodies, Neutralizing: immunology
000280241 650_2 $$2MeSH$$aNeuromuscular Agents: immunology
000280241 650_2 $$2MeSH$$aNeuromuscular Agents: therapeutic use
000280241 650_2 $$2MeSH$$aBlepharospasm: drug therapy
000280241 650_2 $$2MeSH$$aBlepharospasm: immunology
000280241 7001_ $$aAlbrecht, Phillipp$$b1
000280241 7001_ $$aCarr, Warner$$b2
000280241 7001_ $$aHefter, Harald$$b3
000280241 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.70289$$gVol. 32, no. 8, p. e70289$$n8$$pe70289$$tEuropean journal of neurology$$v32$$x1351-5101$$y2025
000280241 8564_ $$uhttps://pub.dzne.de/record/280241/files/DZNE-2025-00919%20SUP1.docx
000280241 8564_ $$uhttps://pub.dzne.de/record/280241/files/DZNE-2025-00919%20SUP2.pptx
000280241 8564_ $$uhttps://pub.dzne.de/record/280241/files/DZNE-2025-00919.pdf$$yOpenAccess
000280241 8564_ $$uhttps://pub.dzne.de/record/280241/files/DZNE-2025-00919.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280241 909CO $$ooai:pub.dzne.de:280241$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280241 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000336$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000280241 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280241 9141_ $$y2025
000280241 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2022$$d2024-12-12
000280241 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000280241 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-12$$wger
000280241 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280241 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NEUROL : 2022$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000280241 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000280241 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x0
000280241 980__ $$ajournal
000280241 980__ $$aVDB
000280241 980__ $$aUNRESTRICTED
000280241 980__ $$aI:(DE-2719)5000014
000280241 9801_ $$aFullTexts